IP Library Patent Application 17939326
Patent Application
App. No. 17/939,326

ISOTOPICALLY LABELED BILE ACID DERIVATIVES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/939,326
Abstract

The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof

Claims (26)

1 . A compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein

R 1 is OH, O-glucuronide, OSO 3 H, SO 3 H, CO 2 R 5 , 14 CO 2 R 5 , C(O)R 6 , 14 C(O)R 6 ;

R 2 is H, D, or OH;

R 3 is OH or O-glucuronide;

R 4 is OH or O-glucuronide;

R 5 is H or substituted or unsubstituted alkyl;

R 6 is NH(CH 2 ) 2 SO 3 H, NHCH 2 CO 2 H, or N(CH 3 )CH 2 CO 2 H or glucuronic acid moieties,

wherein hydrogens in can be replaced with deuterium;

R 11 is Z 11b , hydroxy, halogen, alkoxy, or oxo when Z 11a is not present;

R 16 is Z 16a , hydroxy, halogen, alkoxy, or oxo when Z 16b is not present;

R 23 is Z 23a or alkyl; and

Z 1a , Z 1b , Z 2a , Z 2b , Z 3 , Z 4a , Z 4b , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 11a , Z 11b , Z 12 , Z 14 , Z 15a , Z 15b , Z 16a , Z 16b , Z 17 , Z 18 , Z 19 , Z 20 , Z 21 , Z 22a , Z 22b , Z 23a , Z 23b , Z 24a , Z 24b , or Z 25 is independently selected from H (hydrogen) or D (deuterium), and at least one of Z 1a , Z 1b , Z 2a , Z 2b , Z 3 , Z 4a , Z 4b , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 11a , Z 11b , Z 12 , Z 14 , Z 15a , Z 15b , Z 16a , Z 16b , Z 17 , Z 18 , Z 19 , Z 20 , Z 21 , Z 22a , Z 22b , Z 23a , Z 23b , Z 24a , Z 24b , or Z 25 is D; and

any carbon atom is 12 C, 13 C, or 14 C.

2 . The compound of claim 1 wherein R 2 is H.

3 . The compound of claim 1 wherein R 2 is OH.

4 . The compound of claim 3 wherein R 2 is alpha-OH.

5 . The compound of claim 1 , wherein R 6 is taurine (—NH(CH 2 ) 2 SO 3 H), glycine (—NHCH 2 CO 2 H), or sarcosine (—N(CH 3 )CH 2 CO 2 H).

6 . The compound of claim 1 , wherein compound of Formula I is a compound of Formula II

7 . The compound of claim 1 , wherein compound of Formula I is a compound of Formula III

8 . The compound of claim 1 , wherein compound of Formula I is a compound of Formula IV

9 . The compound of claim 1 , wherein compound of Formula I is a compound of Formula V

10 . The compound of claim 1 , wherein compound of Formula I is a compound of Formula VI

11 . The compound of claim 1 , wherein compound of Formula I is a compound of Formula VII

12 . The compound of claim 1 , wherein compound of Formula I is a compound of Formula VIII

wherein R 1 is 14 CO 2 R 5 or 14 C(O)R 6 .

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
SECURITY INTEREST Recorded May 4, 2023
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 063541/0362 →